In conclusion, the impact of autophagy in different cancers upon anticancer therapy is apparently context-dependent.26 At least in many solid tumors, bortezomib may induce ERK phosphorylation to suppress cathepsin B, and inhibit the catalytic process of autophagy. The gene discussed is CTSB; the disease is cancer.